Characteristics and Outcome of AKT1 ^E17K -Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.

Autor: Smyth LM; Memorial Sloan Kettering Cancer Center, New York, New York. lilsmyth@svhg.ie., Zhou Q; Memorial Sloan Kettering Cancer Center, New York, New York., Nguyen B; Memorial Sloan Kettering Cancer Center, New York, New York., Yu C; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Lepisto EM; Dana-Farber Cancer Institute, Boston, Massachusetts., Arnedos M; Institut Gustave Roussy, Villejuif, France., Hasset MJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Lenoue-Newton ML; Vanderbilt Ingram Cancer Center, Nashville, Tennessee., Blauvelt N; Memorial Sloan Kettering Cancer Center, New York, New York., Dogan S; Institut Gustave Roussy, Villejuif, France., Micheel CM; Vanderbilt Ingram Cancer Center, Nashville, Tennessee., Wathoo C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Horlings H; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands., Hudecek J; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands., Gross BE; Memorial Sloan Kettering Cancer Center, New York, New York., Kundra R; Memorial Sloan Kettering Cancer Center, New York, New York., Sweeney SM; American Association for Cancer Research, Philadelphia, Pennsylvania., Gao J; Memorial Sloan Kettering Cancer Center, New York, New York., Schultz N; Memorial Sloan Kettering Cancer Center, New York, New York., Zarski A; Memorial Sloan Kettering Cancer Center, New York, New York., Gardos SM; Memorial Sloan Kettering Cancer Center, New York, New York., Lee J; American Association for Cancer Research, Philadelphia, Pennsylvania., Sheffler-Collins S; American Association for Cancer Research, Philadelphia, Pennsylvania., Park BH; Vanderbilt Ingram Cancer Center, Nashville, Tennessee., Sawyers CL; Memorial Sloan Kettering Cancer Center, New York, New York., André F; Institut Gustave Roussy, Villejuif, France., Levy M; Vanderbilt Ingram Cancer Center, Nashville, Tennessee., Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, Texas., Bedard PL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Iasonos A; Memorial Sloan Kettering Cancer Center, New York, New York., Schrag D; Dana-Farber Cancer Institute, Boston, Massachusetts., Hyman DM

Publikováno v: Cancer discovery [Cancer Discov] 2020 Apr; Vol. 10 (4), pp. 526-535. Date of Electronic Publication: 2020 Jan 10.

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.

Autor: Ludovini, Vienna¹ oncolab@hotmail.com, Antognelli, Cinzia², Rulli, Antonio³, Foglietta, Jennifer¹, Pistola, Lorenza¹, Eliana, Rulli⁴, Floriani, Irene⁴, Nocentini, Giuseppe⁵, Romana Tofanetti, Francesca¹, Piattoni, Simonetta⁶, Minenza, Elisa⁷, Talesa, Vincenzo Nicola², Sidoni, Angelo⁸, Tonato, Maurizio⁹, Crinò, Lucio¹⁰, Gori, Stefania¹¹, Tofanetti, Francesca Romana¹ (AUTHOR)

Publikováno v: BMC Cancer. 7/26/2017, Vol. 17, p1-11. 11p. 1 Diagram, 4 Charts, 1 Graph.

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.

Autor: Pfeil, Alena M.¹ alena.pfeil@unibas.ch, Vulsteke, Christof^2,3 Christof.Vulsteke@azmmsj.be, Paridaens, Robert² robert.paridaens@uzleuven.be, Dieudonné, Anne-Sophie^4,5 anne-sophie.dieudonne@uzleuven.be, Pettengell, Ruth⁶ rpettengell@sgul.ac.uk, Hatse, Sigrid^2,3 Sigrid.Hatse@med.kuleuven.be, Neven, Patrick⁵ patrick.neven@uzleuven.be, Lambrechts, Diether^7,8 Diether.Lambrechts@vib-kuleuven.be, Szucs, Thomas D.¹ thomas.szucs@unibas.ch, Schwenkglenks, Matthias¹ m.schwenkglenks@unibas.ch, Wildiers, Hans^3,5 hans.wildiers@uzleuven.be

Publikováno v: BMC Cancer. 2014, Vol. 14 Issue 1, p1-20. 20p.

Economic recovery: A measure of the quality of cancer treatment and survivorship?

Autor: Bradley, Cathy J.

Publikováno v: Cancer (0008543X); Dec2015, Vol. 121 Issue 24, p4282-4285, 4p

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.

Autor: Vulsteke, C., Pfeil, A., Schwenkglenks, M., Pettengell, R., Szucs, T., Lambrechts, D., Peeters, M., Dam, P., Dieudonné, A., Hatse, S., Neven, P., Paridaens, R., Wildiers, H.

Publikováno v: Breast Cancer Research & Treatment; Oct2014, Vol. 147 Issue 3, p557-570, 14p